0001104659-20-140307.txt : 20201229 0001104659-20-140307.hdr.sgml : 20201229 20201229215223 ACCESSION NUMBER: 0001104659-20-140307 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201222 FILED AS OF DATE: 20201229 DATE AS OF CHANGE: 20201229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FRATTAROLI JOSEPH CENTRAL INDEX KEY: 0001272668 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39676 FILM NUMBER: 201423916 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc. CENTRAL INDEX KEY: 0001750149 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 678-392-3419 MAIL ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 4 1 tm2039455d1_form4.xml FORM 4 X0306 4 2020-12-22 0 0001750149 Inhibikase Therapeutics, Inc. IKT 0001272668 FRATTAROLI JOSEPH 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 0 1 0 0 Chief Financial Officer Common Stock 2020-12-28 4 C 0 44143 10.00 A 44143 I By Flagship Consulting, Inc. Stock Option (right to buy) 10.00 2020-12-22 4 A 0 100000 0 A 2030-12-22 Common Stock 100000 100000 D Convertible Note 10.00 2020-12-28 4 C 0 441431.52 0 D 2020-12-28 2021-12-31 Common Stock 44143 0 I By Flagship Consulting, Inc. One-third of the option will vest and become exercisable on 12/22/2021, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of the month beginning January 1, 2022. /s/ Milton H. Werner, attorney-in-fact 2020-12-29